Eyenovia, Inc. (NASDAQ:EYEN)’s earnings report is anticipated on April, 1., according to Zacks. Analysts forecast 48.81 % diference or $-0.43 from the $-0.84 EPS from 2018. After $-0.43 EPS report last quarter, Wall Street now predicts 0.00 % EPS growth of Eyenovia, Inc.. The stock decreased 1.32% or $0.07 during the last trading session, hitting $5.23.Currently Eyenovia, Inc. is downtrending after 44.50% change in last March 12, 2018. EYEN has also 33,045 shares volume. EYEN underperformed by 48.87% the S&P500.

Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States.The company has $61.62 million market cap. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.Currently it has negative earnings. The firm was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014.

For more Eyenovia, Inc. (NASDAQ:EYEN) news brought out briefly go to: Benzinga.com, Nasdaq.com, Benzinga.com, Benzinga.com or Globenewswire.com. The titles are as follows: “42 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” brought out on February 13, 2019, “Eyenovia confirms expanded MicroProst Phase III indication to enroll broad patient population for IOP lowering – Nasdaq” on February 13, 2019, “35 Stocks Moving In Monday’s Mid-Day Session – Benzinga” with a publish date: February 11, 2019, “71 Biggest Movers From Yesterday – Benzinga” and the last “Eyenovia to Participate in Two Upcoming Investor Conferences – GlobeNewswire” with publication date: March 04, 2019.